Comment on CMS-2026-1256-0002

Summary: Mental Health America opposes CMS's proposal to disapprove New Technology Add-on Payments (NTAP) for the medication Cobenfy. The organization argues that because Cobenfy offers a novel mechanism of action different from traditional antipsychotics, it provides a vital option for patients who have failed other treatments and are at high risk for rehospitalization.